Abstract:Background: Gliomas, known for their complex and aggressive characteristics, are deeply influenced by the tumor microenvironment. Matrix metalloproteinases (MMPs) play a vital role in shaping this environment, presenting an opportunity for novel treatment strategies. Methods: We collected six bulk RNA datasets, one single-cell RNA sequencing (scRNA-seq) dataset, and gene sets related to Matrix Metalloproteinases (MMPs), Endothelial-Mesenchymal Transformation (EndMT), and sprouting angiogenesis. We computed enrichment scores using Gene Set Variation Analysis (GSVA) and Single-sample Gene Set Enrichment Analysis (ssGSEA). To analyze immune infiltration, we employed the CIBERSORT method. Data analysis techniques included the log-rank test, Cox regression, Kruskal-Wallis test, and Pearson correlation. For single-cell data, we utilized tools such as Seurat and CellChat for dimensionality reduction, clustering, and cell communication analysis. Results: 1. MMP14 was identified as an independent prognostic marker, highly expressed in myeloid cells in recurrent glioblastoma, highlighting these cells as functionally significant. 2. C-C Motif Chemokine Ligand (CCL) signaling from MMP14+ myeloid cells was identified as a critical immune regulatory pathway, with high C-C Motif Chemokine Receptor 1 (CCR1) expression correlating with increased M2 macrophage infiltration and PD-L1 expression. 3. Patients with high MMP14 expression showed better responses to bevacizumab combined chemotherapy. 4. Signaling pathways involving Visfatin, VEGF, and TGFb, emanating from myeloid cells, significantly impact endothelial cells. These pathways facilitate EndMT and angiogenesis in gliomas. 5. Nicotinamide Phosphoribosyltransferase (NAMPT) showed a strong link with angiogenesis and EndMT, and its association with chemotherapy resistance and differential sensitivity to bevacizumab was evident. Conclusions: MMP14+ myeloid cells are critical in promoting tumor angiogenesis via EndMT and in mediating immunosuppression through CCL signaling in glioblastoma. MMP14 and NAMPT serve as vital clinical indicators for selecting treatment regimens in recurrent glioma. The study suggests that a combined blockade of CCR1 and CD274 could be a promising therapeutic strategy.

N-Terminal Polypeptide Derived From Vmip-Ii Exerts Its Antitumor Activity By Inhibiting The Cxcr4 Pathway In Human Glioma

The N-terminal Polypeptide Derived from Viral Macrophage Inflammatory Protein II Reverses Breast Cancer Epithelial-to-mesenchymal Transition Via a PDGFRα-dependent Mechanism

Musashi-1 Enhances Glioblastoma Cell Migration and Cytoskeletal Dynamics through Translational Inhibition of Tensin3

NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer

The Role of SDF-1/CXCR4 Axis in Proliferation,Migration and Invasion of Malignant Glioma Cell Lines

Integrated analysis based on vesicle trafficking‐related genes identifying CNIH4 as a novel therapeutic target for glioma

MicroRNA-21 Inhibitor Sensitizes Human Glioblastoma U251 Stem Cells to Chemotherapeutic Drug Temozolomide

Non-immunogenic, Low-Toxicity and Effective Glioma Targeting MTI-31 Liposomes

New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221.

Multi-targeting Peptide-Functionalized Nanoparticles Recognized Vasculogenic Mimicry, Tumor Neovasculature, and Glioma Cells for Enhanced Anti-glioma Therapy.

Investigation of a Plasmid Containing a Novel Immunotoxin VEGF165‐PE38 Gene for Antiangiogenic Therapy in a Malignant Glioma Model

DDIS-02. AN ENGINEERED IN VITRO SYNTHESIZED PROTEIN ZR30 EXPRESSES ITS ANTI-CANCER EFFECT IN THE EXTRACELLULAR COMPARTMENT OF DIFFERENT GLIOMA CELL SUBPOPULATIONS IN INTRACRANIAL XENOGRAFT MODELS

MicroRNA-509-3p Inhibits Cell Proliferation and Invasion Via Downregulation of X-linked Inhibitor of Apoptosis in Glioma.

Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model

An MSN-PEG-IP Drug Delivery System and IL13Rα2 As Targeted Therapy for Glioma.

Improved Therapeutic Efficacy Using Vaccination with Glioma Lysate-Pulsed Dendritic Cells Combined with IP-10 in Murine Glioma

MicroRNA-16 Inhibits Glioma Cell Growth and Invasion Through Suppression of BCL2 and the Nuclear Factor-Κb1/mmp9 Signaling Pathway.

A Tropomyosin-Like Meretrix Meretrix Linnaeus Polypeptide Inhibits the Proliferation and Metastasis of Glioma Cells Via Microtubule Polymerization and FAK/Akt/MMPs Signaling.

Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2

The Effects of VEGF and Smac/DIABLO on Apoptosis and Chemosensitivity of Human Glioma Cells

Bioinformatics analysis of MMP14+ myeloid cells affecting endothelial-mesenchymal transformation and immune microenvironment in glioma